Rezolute   Report issue

For profit Phase 1 Phase 2
Founded: Indiana PA United States (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2013
NCT01828723
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Antria | Antria Inc. | Rezolute

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Congenital Hyperinsulinism (Phase 2)

Facies (Phase 2)

Hyperinsulinism (Phase 2)

Lipodystrophy (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 5